Combination of curcumin and gemcitabine suppresses tumor progression and decreases the level of LAT2, CK19 and HMGB1 in a gemcitabine-resistant CCA xenograft mouse model and in a hamster CCA model. Here, KRT19 is linked to neoplasm.